ASH Clinical News ACN_4.11_Full Issue_web | Page 22

Pulling Back the Curtain Robert Glassman, MD In this edition, Robert Glassman, MD, talks about the “risky yet refreshing” transition from clinical practice to the financial world and explains how grand rounds saved his life. Dr. Glassman is managing director and vice chairman in the Global Healthcare Investment Banking Group at Credit Suisse. Previously, he worked as a consultant at McKinsey & Company and a private equity partner at OrbiMed Advisors. Dr. Glassman in his home office. When you began your career in medicine, who inspired you to pursue hematology? I’ve been sparked by several mentors from distinct phases of my life. In science and hematol- ogy, there are four who come to mind. Douglas B. Cines, MD, was my attending during my internal medicine residency at the Hospital of the University of Pennsylvania. He was a true “triple threat” and the first one who got me excited about hematology. Ralph Nachman, MD, was chair of medicine at Weill Cornell Medical College in New York, and he was another hema- tology triple threat who demon- strated exemplary leadership. He knew how to “cut to the chase.” In any presentation, he methodi- cally extracted key points of the research or clinical case to share with the audience. (Editor’s note: Dr. Nachman also was the winner of the 2016 American Society of Hematology Basic Science Mentor Award.) Morton Coleman, MD, was a creative and brilliant lymphoma specialist at Cornell. I learned so much from him about both he- matology and life – wisdom that he imparted in a down-to-earth manner, splashed with wonderful humor. During my training, he was one of the few attendings who strongly supported my quest to enter the business world. The late Hidesaburo Hanafusa, PhD, who won the 1982 Albert Lasker Basic Medical Research Award for his work demonstrating that oncogenes come from proto- oncogenes, played an important role in my career. He took me into his lab, even though I hadn’t a shred of research experience, and instilled in me a deep appreciation for rigorous scientific investigation. 20 ASH Clinical News Having explored a few career paths already, are there any other fields that you could see yourself pursuing? Well, I have traversed four or five careers already – clinical medicine, laboratory research, management consulting, and public and private equity – but all involved health care and/or science to some extent. Could I have been a great trial lawyer? Or a judge? Or a chef? I’m not sure, but I doubt it. Sci- ence, innovation, and taking care of people have always been my unwavering passions. I always felt privileged to be a doctor, touching someone’s life at his or her most tragic and needful moments. No matter what I did, science a